US Senator seeks answers from drugmakers on providing required discounts

27 September 2013

US Senator Charles Grassley (Republican, Iowa) and Ranking Member of the Committee on the Judiciary US Senate, has written to two drug companies on behalf of an Iowa hospital that is not receiving required discounts on two drugs, despite a federal program to help uninsured patients with deeply discounted drugs.

Sen Grassley says he is seeking information from the companies and also more oversight from the federal agency in charge of the drug program to ensure the companies provide the required discounts.

“The program is designed to help patients who have no means of receiving prescription drugs except through a hospital or community health center that agrees to treat them,” Sen Grassley said, adding: “The federal agency in charge of the program has to make sure the program is working. That means making sure hospitals get the discounted drugs they’re entitled to receive so they can treat patients in need."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK